Press release
Gallbladder Cancer Clinical Trials Analysis 2025 Innovative Combinations and Immunotherapy Strategies Reshape the Treatment Landscape | DelveInsight
Checkpoint inhibitors, including PD-1 and PD-L1 antibodies, are being investigated alone and in combination with chemotherapy to extend overall survival in advanced cases. Parallel trials are assessing FGFR2, HER2, and IDH pathway inhibitors, offering precision-based approaches for biomarker-driven subsets of gallbladder cancer.
Innovative modalities such as antibody-drug conjugates and tumor vaccines are also advancing, with early results indicating potential for durable responses. Global collaborations are enabling adaptive trial designs and accelerated recruitment, particularly in high-prevalence regions such as South Asia and Latin America.
With several late-stage trials maturing in 2025, the gallbladder cancer treatment landscape is poised for transformation, driven by immuno-oncology and precision medicine strategies that aim to improve outcomes in this hard-to-treat cancer significantly
Explore the full pipeline analysis for gallbladder cancer and uncover key opportunities @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Gallbladder Cancer Pipeline Report
• DelveInsight's Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline drugs for Gallbladder Cancer treatment.
• The leading Gallbladder Cancer companies include Celgene, MedImmune, Ohara Pharmaceuticals, and others are evaluating their lead assets to improve the Gallbladder Cancer treatment landscape.
• Key Gallbladder Cancer pipeline therapies in various stages of development include Zygel, BPN14770, AUT00206, Pridopidine, MG01CI, Arbaclofen, Ganaxolone, AFQ056, NNZ-2566, RO4917523, and others.
• In December 2024, Checkpoint Therapeutics, Inc. announced that the FDA approved UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.
• In December 2024, the FDA approved tislelizumab-jsgr (Tevimbra) in combination with platinum- and fluoropyrimidine-based chemotherapy for first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1.
• In December 2024, Jazz Pharmaceuticals announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for intravenous use was recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines as a category 2A treatment option for Biliary Tract Cancers (BTC).
• In December 2014, Ipsen Biopharmaceuticals announced that the FDA approved SOMATULINE DEPOT for the treatment of GEP-Neuroendocrine Tumors in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).
• In April 2024, Perspective Therapeutics announced the selection of investigational product [212Pb]VMT-a-NET for the treatment of certain patients with neuroendocrine tumors by the FDA to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.
Request a sample and discover the recent breakthroughs happening in the Gallbladder Cancer pipeline landscape @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Overview
Gallbladder cancer is a rare cancer that begins in the gallbladder, a small organ located under the liver responsible for storing bile, which aids in digestion. Most cases are adenocarcinomas, originating from glandular cells lining the gallbladder. It typically develops due to DNA mutations that cause abnormal, uncontrolled cell growth. Gallbladder cancer is more common in middle-aged women, particularly those with a history of gallstones, but it can also affect men. The cancer may present as various types, including papillary adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma. Due to its rarity and the often lack of symptoms in the early stages, it is frequently diagnosed at an advanced stage, making early detection vital for better treatment outcomes.
Find out more about Gallbladder Cancer medication @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Treatment Analysis: Drug Profile
Durvalumab: Celgene
Durvalumab, developed by Celgene, is a human immunoglobulin G1 kappa monoclonal antibody currently under development for the treatment of gallbladder cancer. It works by inhibiting the immune response through blocking the interaction of PD-L1 with PD-1 and CD80. In Phase I clinical trials, the drug has shown promising efficacy and a favorable safety profile.
ONC 201: Ohara Pharmaceuticals
ONC 201, a novel drug candidate from Ohara Pharmaceuticals, is an orally administered small molecule being developed for the treatment of gallbladder cancer. It functions by inactivating the Akt/ERK signaling pathway, which leads to the upregulation of the proapoptotic immune cytokine TRAIL, promoting cancer cell death.
Learn more about the novel and emerging Gallbladder Cancer pipeline therapies @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Gallbladder Cancer Pipeline Report
• Coverage: Global
• Key Gallbladder Cancer Companies: Celgene, MedImmune, Ohara Pharmaceuticals, and others.
• Key Gallbladder Cancer Pipeline Therapies: Zygel, BPN14770, AUT00206, Pridopidine, MG01CI, Arbaclofen, Ganaxolone, AFQ056, NNZ-2566, RO4917523, and others.
Dive deep into rich insights for drugs used for Gallbladder Cancer treatment; visit @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Gallbladder Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Gallbladder Cancer Pipeline Therapeutics
6. Gallbladder Cancer Pipeline: Late-Stage Products (Phase III)
7. Gallbladder Cancer Pipeline: Late-Stage Products (Phase III)
8. Gallbladder Cancer Pipeline: Mid-Stage Products (Phase II)
9. Gallbladder Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gallbladder Cancer Clinical Trials Analysis 2025 Innovative Combinations and Immunotherapy Strategies Reshape the Treatment Landscape | DelveInsight here
News-ID: 4202312 • Views: …
More Releases from DelveInsight Business
Familial Chylomicronemia Syndrome Market and Epidemiology 2034: Treatment Market …
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome…
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market to Grow Positively …
(New York, Nevada, Las Vegas), DelveInsight's "Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Recurrent Head and Neck Cancer Squamous Cell Carcinoma market share of the individual therapies, current and forecasted Recurrent Head and Neck Cancer Squamous Cell Carcinoma market size from 2019 to 2032 segmented by seven major markets. The report also offers…
More Releases for Gallbladder
Gallbladder Surgery Under Dr. Moein in Los Angeles
Gallbladder surgery has become a preferred option for many in Los Angeles seeking relief from painful gallstones and cholecystitis. At Healthy Life Bariatrics, board-certified surgeon Dr. Babak Moein performs minimally invasive laparoscopic gallbladder removal, offering patients faster recovery, smaller incisions, and fewer complications.
More and more patients in Los Angeles are turning to minimally invasive gallbladder surgery to treat painful symptoms of gallstones and cholecystitis. Surgeons in the area, including trusted…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Cancer Treatment Market Expands With Emergence of Novel Chemotherape …
Gallbladder Cancer Treatment Market Overview
The Gallbladder Cancer Treatment Market is projected to grow from USD 720 Million in 2025 to USD 1.4 Billion by 2032, at a CAGR of 10.1% during the forecast period.
Coherent Market Insights is pleased to release its latest Gallbladder Cancer Treatment Market research report, offering an in-depth analysis of the U.S. Gallbladder Cancer Treatment Market Landscape from 2025 to 2032. This report delivers reliable projections across…
Gallbladder Cancer Market to Rise by 2032 | Celgene, MedImmune, Ohara Pharmaceut …
DelveInsight's "Gallbladder Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gallbladder Cancer, historical and forecasted epidemiology as well as the Gallbladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Gallbladder Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gallbladder Cancer market size…
Gallbladder Cancer Therapeutics Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Gallbladder Cancer Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Gallbladder Cancer Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
